Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.32 |
| ▸ | QPCT | Q16769 | 2/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | POLQ | O75417 | 4/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033115 | 0.79 | MAOA (0.53) | MAOA | |
| SCHEMBL6097287 | 0.71 | ESR1 (0.31) | — | |
| SCHEMBL3046255 | 0.71 | MAOA (0.41) | MAOA | |
| SCHEMBL6727354 | 0.70 | MAOB (0.48) | MAOA | |
| SCHEMBL3035027 | 0.67 | MAOA (0.53) | MAOA | |
| SCHEMBL6085956 | 0.63 | MAOA (0.33) | MAOA | |
| SCHEMBL6727665 | 0.61 | DRD4 (0.34) | — | |
| SCHEMBL6725869 | 0.61 | HPGD (0.34) | PIK3CA | |
| SCHEMBL15015207 | 0.60 | MAP4K1 (0.37) | HDAC1HDAC8HDAC6PIK3CA | |
| SCHEMBL8281158 | 0.60 | F10 (0.39) | HDAC1HDAC8HDAC6PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | HDAC1 44/4885HDAC8 209/4885HDAC6 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.